Article PDF :

Veiw Full Text PDF

Article type :

1

Author :

Yasser Ghanem Madloul,Kazem Musa Youssef,Naseer Waad Hassan

Volume :

2

Issue :

8

Abstract :

Abstract In America, pancreatic cancer ranks as the fourth most common killer. Adismal outlook awaits patients diagnosed with pancreatic cancer. When diagnosed, mostindividuals have tumours that cannot be removed. The clinical experience with stereotacticbody radiation (SBRT) for pancreatic cancer has demonstrated excellent local control, whichis very encouraging. Intensive systemic chemotherapy can be maintained during SBRT'sbrief treatment duration, which is a major benefit. Pancreatic adenocarcinoma patients havejust one curative therapy option, and that is surgery. Rates of local recurrence and/or distantmetastases are still high, leading to poor long-term results, even when patients who areconsidered resectable undergo rigors surgical care. Patients who have undergone resectionhave been the focus of research into adjuvant therapies (ATs), which include chemotherapyand chemoradiation therapy (CRT), with the goal of improving survival rates and reducingrecurrence rates. Evidence for adjuvant radiation therapy (RT) is inconsistent, in contrast tothat for adjuvant chemotherapy, which consistently improves results. Radiation has shownpromise in improving local control, but this has not necessarily translated into better survivalrates for patients. Limitations in generalizability stem from early trials' use of less-than-idealradiation methods. More optimised RT techniques are being used in recent and continuingtrials to elucidate its significance in therapeutic strategies. New radiation methods are alsobeing studied, including stereotactic body RT (SBRT) and intensity modulated RT (IMRT).These efforts are being made in the hopes that they may decrease toxicity rates and enhancedisease-related outcomes. Controversy surrounds adjuvant RT's function. Due to their use ofwhat is now known as sub-optimal RT, early trials were defective and had inconsistentoutcomes. Current RTOG 08-48 and other adjuvant RT trials use evidence-based volumetargets and strict quality control measures. The function of adjuvant radiation in patientswith resected PC will be better understood based on the findings of this research. Thepotential for increasing the therapeutic window and bettering disease outcomes is held bythe incorporation of contemporary radiation techniques like SBRT and IMRT, whichmaximise dosage to target volumes while minimising dose to normal tissues.